Infectious Complications after Monoclonal Antibody Therapy in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 27-33, 2011.
Article
in English
| WPRIM
| ID: wpr-788434
ABSTRACT
BACKGROUND:
We evaluated characteristics of infectious complications in pediatric patients who received monoclonal antibody (mAb) therapy after allogeneic hematopoietic cell transplantation (HCT).METHODS:
Between February 2004 and May 2009, 17 pediatric patients (<19 years at diagnosis) who received mAbs were identified as a study group (mAb group). One hundred twenty-two pediatric allogeneic HCT patients (<19 years at diagnosis) who did not receive mAb during the same period were identified as a control group (non-mAb group). A retrospective chart review of medical records was performed for the incidence of infectious complications and mortality.RESULTS:
In the mAb group, 12 of the 17 patients (70.6%) had 29 infectious complications (1.71 episodes per person), whereas 89 of the 122 patients (73.8%) had 162 infectious complications (1.32 episodes per person) in the non-mAb group (P=0.838). Although, there were no significant differences in characteristics or incidence of infectious complications between the two groups, the infection-associated mortality rate was significantly higher in the mAb group compared to non-mAb group (29.4% vs. 8.2% P=0.021; RR 3.44, 95% CI, 1.407 to 8.433).CONCLUSION:
The mAb therapy was associated with significantly high mortality in pediatric allogeneic HCT recipients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Medical Records
/
Incidence
/
Retrospective Studies
/
Cell Transplantation
/
Transplants
Type of study:
Incidence study
/
Observational study
/
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Clinical Pediatric Hematology-Oncology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS